- Home
- URGN vs OUST Comparison
URGN vs OUST Comparison
Compare URGN & OUST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- OUST
- Stock Information
- Founded
- URGN 2004
- OUST 2015
- Country
- URGN United States
- OUST United States
- Employees
- URGN N/A
- OUST N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- OUST Industrial Machinery/Components
- Sector
- URGN Health Care
- OUST Technology
- Exchange
- URGN Nasdaq
- OUST Nasdaq
- Market Cap
- URGN 1.1B
- OUST 1.1B
- IPO Year
- URGN 2017
- OUST N/A
- Fundamental
- Price
- URGN $27.39
- OUST $21.63
- Analyst Decision
- URGN Strong Buy
- OUST Strong Buy
- Analyst Count
- URGN 8
- OUST 6
- Target Price
- URGN $28.50
- OUST $31.33
- AVG Volume (30 Days)
- URGN 1.4M
- OUST 2.8M
- Earning Date
- URGN 11-06-2025
- OUST 11-04-2025
- Dividend Yield
- URGN N/A
- OUST N/A
- EPS Growth
- URGN N/A
- OUST N/A
- EPS
- URGN N/A
- OUST N/A
- Revenue
- URGN $96,516,000.00
- OUST $137,298,000.00
- Revenue This Year
- URGN $35.07
- OUST $33.30
- Revenue Next Year
- URGN $117.83
- OUST $36.50
- P/E Ratio
- URGN N/A
- OUST N/A
- Revenue Growth
- URGN 8.00
- OUST 30.20
- 52 Week Low
- URGN $3.42
- OUST $6.34
- 52 Week High
- URGN $27.98
- OUST $41.65
- Technical
- Relative Strength Index (RSI)
- URGN 74.68
- OUST 38.85
- Support Level
- URGN $24.69
- OUST $18.52
- Resistance Level
- URGN $26.28
- OUST $22.49
- Average True Range (ATR)
- URGN 1.87
- OUST 1.97
- MACD
- URGN 0.32
- OUST -0.25
- Stochastic Oscillator
- URGN 95.93
- OUST 37.26
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.